

## Structure based design and anti-breast cancer evaluation of some novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor inhibitors

Zahra Haghhighjoo<sup>1,2</sup>, Zahra Rezaei<sup>1</sup>, Mansooreh Jaberipoor<sup>3</sup>, Samaneh Taheri<sup>1</sup>,  
Meysam Jani<sup>1</sup>, and Soghra Khabnadideh<sup>1,\*</sup>

<sup>1</sup>Pharmaceutical Sciences Research Center, Pharmacy School, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.

<sup>2</sup>Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.

<sup>3</sup>Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.

### Abstract

Quinazoline is one of the most widespread scaffolds amongst natural and synthetic bioactive compounds. Recently the quinazoline derivatives and in particular the 4-anilinoquinazolines have attracted much attention for their anticancer properties due to their capability to stabilize the kinase activity of epidermal growth factor receptor (EGFR). A series of fifteen previously designed and synthesized 4-anilinoquinazoline analogs (**4-18**) were evaluated for cytotoxic activity on two breast cancer cell lines (MCF-7 and MDA-MB-468). Ligand efficiency and binding mode studies were also done and evaluated for their potentially EGFR inhibitory effects in comparison with imatinib and erlotinib as reference drugs. Among the tested 4-anilinoquinazolines, compound **11**, which contains diethoxy at phenyl ring and morpholino pendants at positions 5 and 7 of the quinazoline ring, demonstrated the most potent biological activity on both cell lines. Our new quinazoline derivatives with different substituents such as cyclic or linear ethers and flour groups may be a promising cytotoxic lead compounds for further anti-breast cancer research.

**Keywords:** 4-Anilinoquinazoline; Cytotoxic activity; Docking; EGFR.

### INTRODUCTION

Overexpression of luminal (positive for estrogen or progesterone receptors) and epidermal growth factor receptors 2 (EGFR2 or HER2) play essential roles in breast cancer (1). There is an intractable and an aggressive subtype of breast cancer that is defined by the absence of estrogen, progesterone receptors, and HER2 which known as triple-negative breast cancer (TNBC). The therapeutic effect of EGFR inhibitors as potent suppressors of TNBC progression have been underwhelming (2,3). Recent improvements in the identification of EGFR inhibitors have created hope for the modulation of uncontrolled cell growth in cancer therapy especially for solid tumors. In recent years, many EGFR inhibitors with different molecular scaffolds have been discovered (4-6). Among them, ATP competitive inhibitors of 4-anilinoquinazolines analogs like erlotinib and gefitinib have been approved (7-10). There are also some reports showing the hopeful benefits

from imatinib and combined treatment with a dual inhibitor of EGFR and imatinib (11,12). But unfortunately, these EGFR inhibitors have been disappointing in EGFR overexpressed TNBC because of signal pathways of Akt and HER3 in cells that could cause acquired resistance. Herein, in order to search for new promising anti-breast cancer compounds, a series of 4-anilinoquinazoline derivatives were designed and evaluated against imatinib using two cell lines MCF-7 and MDA-MB-468 (Fig. 1). For this purpose we attempted to set up predictive models in *in silico* analysis to design EGFR-inhibitors. Subsequently fifteen new anilinoquinazoline derivatives containing desirable substituents were considered to optimize the favorable scaffold. The main points for this optimization were ability of making polar interaction and inhibition of the tyrosine kinase activity.

\*Corresponding author: S. Khabnadideh  
Tel: +98-7132425305, Fax: +98-7132424126  
Email: khabns@sums.ac.ir

#### Access this article online



Website: <http://rps.mui.ac.ir>

DOI: 10.4103/1735-5362.235163




Fig. 1. Structure based design of anti-breast cancer agents.

## MATERIALS AND METHODS

### Chemistry

All new synthesized compounds were chose from our previous study (13,14). A brief of general procedure for synthesis and their chemical structures are mentioned here. 4-aminoquinazoline derivatives were prepared from difluoro or dichloro anthranilic acid through 3 or 4 step reactions according to the procedure shown in Scheme 1. All compounds contained aniline pendant with various electron donating and withdrawing groups at position 4 of quinazoline ring. Chemical structures of all compounds are summerized in Table 1.


### Assesments of *in vitro* anticancer activities

The effects of all the newly synthesized compounds on cell proliferation were evaluated by thiazolyl blue tetrazolium bromide (MTT) assay in two human breast carcinoma cell lines (MCF-7 and MDA-MB-468) (15). Cell lines were purchased from the national cell bank of Pasteur Institute of Iran (Tehran, I.R. Iran). In brief, cells from different cell lines were seeded in 96-well plates and incubated for 24 h to allow cell attachment. The cells were then incubated for another 24 h with various concentrations of the tested compounds and washed in phosphate buffered

saline (PBS). Then 20  $\mu$ L of MTT solution (5 mg/mL) were added to each well and an additional 4 h of incubation at 37  $^{\circ}$ C were done, and then the medium was discarded. Afterward dimethyl sulfoxide (DMSO) (60  $\mu$ L) was added to each well, and the solution was vigorously mixed to dissolve the purple tetrazolium crystals. Finally the absorbance of each well was measured by plate reader at a test wavelength of 490 nm against a standard reference solution at 490 nm (16,17).

### *In silico* studies

The chemical structures were drawn for geometry optimization using HyperChem software (Version 7, Hypercube Inc) under molecular mechanics MM+ method. PYRX molecular docking software has been employed for docking studies. The crystal structure of the EGFR-erlotinib complex was obtained from <http://www.rcsb.org> (PDB ID: 1M17). All bound waters and ligand were removed. The cubic grid box was created in 60  $\text{Å}$  size (x, y, and z) and the center was placed on catalytic active site region where the erlotinib as native ligand was embedded. The properties (ligand efficiency (LE)) were calculated according to the presented method on <http://www.molinspiration.com/cgi-bin/properties> and binding mode analysis and images were generated with PYMOL.



**Scheme 1.** Synthesis pathway for the preparation of 4-aminoquinazoline derivatives. Reagents and conditions: (i) Formamide, micro wave; (ii)  $\text{SOCl}_2$ , dimethylformamide (DMF), reflux, 20 h; (iii) Aniline derivatives,  $\text{iPrOH/DMF}$ , reflux, 20 h; (iv)  $\text{NaH}$ ,  $\text{ROH}$ ,  $\text{DMF}$ , reflux, 7 h.

**Table 1.** Inhibition of breast carcinoma proliferation (MCF-7 and MDA-MB-468) by compounds **4-18**.

| Entry.   | R | Ar | MCF-7 ( $\text{IC}_{50}, \mu\text{M}$ ) | MDA-MB-468 ( $\text{IC}_{50}, \mu\text{M}$ ) |
|----------|---|----|-----------------------------------------|----------------------------------------------|
| 4        |   |    | 108                                     | 155                                          |
| 5        |   |    | 85                                      | 129                                          |
| 6        | - |    | 60                                      | 123                                          |
| 7        |   |    | 89                                      | 134                                          |
| 8        |   |    | 76                                      | 126                                          |
| 9        |   |    | 82                                      | 100                                          |
| 10       |   |    | 43                                      | 90                                           |
| 11       |   |    | 31                                      | 50                                           |
| 12       |   |    | 50                                      | 110                                          |
| 13       |   |    | 60                                      | 130                                          |
| 14       |   |    | 50                                      | 110                                          |
| 15       |   |    | 69                                      | 139                                          |
| 16       |   |    | 72                                      | 153                                          |
| 17       |   |    | 76                                      | 106                                          |
| 18       |   |    | 91                                      | 160                                          |
| Imatinib | - | -  | 25                                      | 45                                           |

## RESULTS

### *In vitro anticancer activity*

The quinazoline derivatives were screened in three different groups according to their chemical structures, including: derivatives of difluoro groups at positions 6 and 7 of the quinazoline ring (**4-8**), derivatives with cyclic diether substitutions at positions 5 and 7 of the quinazoline ring (**9-13**) and derivatives containing linear diether substitutions at positions 5 and 7 of the quinazoline core (**14-18**). As shown in Table 1, all compounds showed better anti-proliferation activity against MCF-7 ( $IC_{50} = 31-106 \mu M$ ) than MDA-MB-468 ( $IC_{50} = 50-160 \mu M$ ) cell line. These data indicated compound **11** bearing diethoxy phenyl and morpholine ether pendants was the most potent cytotoxic agent with  $IC_{50} = 31$  and  $50 \mu M$  for MCF-7 and MDA-MB-468 cell lines, respectively. Among tested compounds in difluoro groups (**4-8**), compound **6** (Ar: 2,5-diethoxy phenyl) exhibited the minimum  $IC_{50}$  value for cytotoxic activity against the MCF-7 cell line. In the second group with morpholine moiety as cyclic ether at positions 6 and 7 of the quinazoline backbone (**9-13**) the order of cytotoxic activity was **11** (Ar: 2,5-diethoxy phenyl) > **10** (Ar: 2-chloro-6-methyl phenyl) > **12** (Ar: 3-benzonitrile) > **13** (Ar: 2-benzonitrile) > **9** (Ar: phenyl) with the range of  $IC_{50}$  values between 31 to 82  $\mu M$ . In the third group of compounds with linear diether substitutions at positions 5 and 7 of the quinazoline core (**14-18**) the order of cytotoxic activity was **14** (Ar: 2-benzonitrile) > **15** (Ar: 3-benzonitrile) > **16** (Ar: 2-benzonitrile) > **17** (Ar: 3-benzonitrile) > **18** (Ar: 2-benzonitrile) with the range of  $IC_{50}$  values between 50-91  $\mu M$ . The  $IC_{50}$  values for MDA-MB-468 cell line for all compounds were increased up to 100  $\mu M$ , except compounds **10** and **11** with  $IC_{50}$  values 90 and 50  $\mu M$ , respectively.

### *In silico studies*


#### *Docking analysis*

After docking the designed compounds into the active site of the EGFR complex structure, most of them showed better binding energy in comparison to erlotinib (-7.2 kcal/mol) as cognate ligand. Compound **7** with substitution of difluoro groups at positions 6 and 7 of the

quinazoline ring and 2-benzonitrile ring seems to be a good lead molecule, which represented binding energy of -8.7 Kcal/mol. In the case of another cyano counterpart, compounds with cyclic and linear diether substituent, though having higher binding energy, but still was comparable with the standard drug (Fig. 2). Moreover the polar interactions with desirable residues in 8 Å distance may be improving the inhibitory activity of the ligands. As listed in Table 2, most of the compounds potentially are able to exhibit hydrogen bonds with Thr766 and Met769. Apart from N<sub>1</sub> and N<sub>3</sub>, the O from ether substitutes on compounds **6** and **8** and also cyano group in compounds **12**, **7**, **15**, **16**, **17**, and **18** could participate in a polar interaction. Binding of a morpholine ring in compounds **10** and ether chain in **16** with Cys773 may be improving inhibitory effects of the compounds. The non-contact residues in most of the binding site are Leu694, Lys721, Ala719, Gly772 and Pro770.

#### *Efficiency indices*

The concept of LE has been widely reported in drug discovery process of fragments, hits and lead selection and optimization. Different equations related to the potency and molecular properties used as LE definition in literatures. The ratio of potency to the molecular weight (MW) (define as  $pIC_{50}/MW$ ) and to the vanderwaals polar surface area (PSA) (define as  $pIC_{50}/PSA$ ) were utilized for two definitions of LE: binding efficiency index (BEI) and surface-binding efficiency index (SEI) (18-20). Most of the tested compounds had BEI more than imatinib as standard drug on both selected cell lines. As shown in Table 3, BEI of the cyclic ethers substituted compounds (**9-13**) were less than imatinib but their SEI were similar to this agent. Neither cyclic (**9-13**) nor linear (**14-18**) ethers substituted compounds but difluoro substitute's compounds (**4-8**) were active. Other normalizing parameters which used to estimate efficiencies are the ratio of  $\Delta G$  and the number of non-hydrogen atoms, MW and PSA. Comparisons of the tested compounds with erlotinib indicated that compounds **9-13** had the closest values for these parameters to the reference drug.



**Fig. 2.** Binding mode of compounds **9**, **13**, and **17** (carbons, yellow; oxygens, red) with epidermal growth factor receptor (EGFR) enzyme (PDB ID: 1M17). The yellow dotted lines show the hydrogen bonds interaction.

**Table 2.** Polar distance and binding site residues.

| Entry     | $\Delta G$ | Polar contact | Ligand element                       | residue | Distance (Å) |
|-----------|------------|---------------|--------------------------------------|---------|--------------|
| 4         | -7.9       | 2             | N <sub>1</sub>                       | Met769  | 3.3          |
|           |            |               | N <sub>3</sub>                       | Thr766  | 2.4          |
| 5         | -8.5       | 1             | N <sub>1</sub>                       | Met769  | 2.7          |
|           |            |               | C5-OEt                               | Thr766  | 3.1          |
| 6         | -7.5       | 2             | N <sub>1</sub>                       | Met769  | 2.1          |
|           |            |               | N <sub>3</sub>                       | Met769  | 3.0          |
| 7         | -8.7       | 3             | N <sub>1</sub>                       | Thr830  | 2.8          |
|           |            |               | N <sub>1</sub>                       | Asp831  | 2.6          |
|           |            |               | N <sub>1</sub>                       | Met769  | 2.1          |
| 8         | -8.2       | 2             | O                                    | Thr766  | 3.1          |
|           |            |               | N <sub>1</sub>                       | Met769  | 2.6          |
| 9         | -7.8       | 1             | N <sub>1</sub>                       | Met769  | 2.5          |
|           |            |               | O                                    | Cys773  | 3.1          |
| 10        | -8.6       | 2             | (in morpholine ring)                 |         |              |
|           |            |               | N <sub>1</sub>                       | Met769  | 2.5          |
| 11        | -7.8       | 1             | N <sub>1</sub>                       | Met769  | 2.1          |
|           |            |               | CN                                   | Thr766  | 3.0          |
| 12        | -8.2       | 2             | N <sub>1</sub>                       | Met769  | 2.2          |
|           |            |               | O                                    | Thr766  | 3.1          |
| 13        | -8.5       | 1             | N <sub>1</sub>                       | Met769  | 2.2          |
|           |            |               | O                                    | Thr766  | 3.1          |
| 14        | -7.8       | 1             | N <sub>1</sub>                       | Met769  | 2.2          |
|           |            |               | N <sub>1</sub>                       | Met769  | 2.2          |
| 15        | -7.6       | 2             | CN                                   | Thr766  | 3.1          |
|           |            |               | N <sub>1</sub>                       | Met769  | 2.1          |
| 16        | -7.4       | 3             | OCH <sub>3</sub><br>(in ether chain) | Cys773  | 3.3          |
|           |            |               | CN                                   | Asp831  | 3.5          |
|           |            |               | N <sub>1</sub>                       | Met769  | 2.3          |
| 17        | -7.0       | 3             | CN                                   | Thr766  | 3.2          |
|           |            |               | CN                                   | Leu764  | 3.5          |
| 18        | -7.6       | 2             | N <sub>1</sub>                       | Met769  | 2.1          |
|           |            |               | N                                    | Asp831  | 3.3          |
| Erlotinib | -7.2       | 1             | N <sub>1</sub>                       | Met769  | 3.2          |

**Table 3.** Efficiency Indices: definitions and idealized reference values.

| Entry     | pIC <sub>50</sub><br>MCF7 | BEI <sup>1</sup><br>MCF7 | SEI <sup>2</sup><br>MCF7 | pIC <sub>50</sub><br>MDA-468 | BEI<br>MDA-468 | SEI<br>MDA-468 | LE <sup>3</sup> | Estimated<br>BEI <sup>4</sup> | Estimated<br>SEI <sup>5</sup> |
|-----------|---------------------------|--------------------------|--------------------------|------------------------------|----------------|----------------|-----------------|-------------------------------|-------------------------------|
| 4         | 3.97                      | 15.42                    | 10.49                    | 3.81                         | 14.81          | 10.08          | -0.416          | 30.71                         | 20.89                         |
| 5         | 4.07                      | 13.32                    | 10.77                    | 3.89                         | 12.72          | 10.29          | -0.405          | 27.80                         | 22.48                         |
| 6         | 4.22                      | 12.23                    | 7.50                     | 3.91                         | 11.32          | 6.95           | -0.300          | 21.72                         | 13.33                         |
| 7         | 4.05                      | 14.35                    | 6.58                     | 3.87                         | 13.72          | 6.29           | -0.414          | 30.82                         | 14.12                         |
| 8         | 4.12                      | 12.80                    | 8.75                     | 3.90                         | 12.12          | 8.29           | -0.373          | 25.49                         | 17.43                         |
| 9         | 4.09                      | 8.52                     | 5.03                     | 4.00                         | 8.34           | 4.92           | -0.223          | 16.26                         | 9.60                          |
| 10        | 4.37                      | 8.27                     | 5.38                     | 4.05                         | 7.66           | 4.98           | -0.232          | 16.28                         | 10.58                         |
| 11        | 4.51                      | 7.94                     | 4.52                     | 4.30                         | 7.58           | 4.31           | -0.190          | 13.74                         | 7.82                          |
| 12        | 4.30                      | 8.52                     | 4.10                     | 3.96                         | 7.85           | 3.77           | -0.222          | 16.25                         | 7.80                          |
| 13        | 4.22                      | 8.37                     | 4.02                     | 3.89                         | 7.70           | 3.70           | -0.227          | 16.64                         | 8.00                          |
| 14        | 4.30                      | 10.18                    | 4.36                     | 3.96                         | 9.37           | 4.02           | -0.245          | 17.99                         | 7.71                          |
| 15        | 4.16                      | 9.85                     | 4.22                     | 3.86                         | 9.13           | 3.91           | -0.232          | 17.04                         | 7.31                          |
| 16        | 4.14                      | 9.81                     | 4.20                     | 3.82                         | 9.03           | 3.87           | -0.242          | 17.75                         | 7.61                          |
| 17        | 4.12                      | 9.75                     | 4.18                     | 3.98                         | 9.41           | 4.03           | -0.229          | 16.81                         | 7.21                          |
| 18        | 4.04                      | 10.25                    | 4.10                     | 3.80                         | 9.62           | 3.85           | -0.245          | 19.27                         | 7.71                          |
| Imatinib  | 4.60                      | 9.32                     | 5.33                     | 4.35                         | 8.81           | 5.04           | -0.227          | 17.02                         | 9.74                          |
| Erlotinib | -                         | -                        | -                        | -                            | -              | -              | -0.248          | 18.30                         | 9.63                          |

<sup>1</sup>Binding efficiency index (BEI), pIC<sub>50</sub>/molecular weight reference value = 27.0; <sup>2</sup>surface-binding efficiency index (SEI), pIC<sub>50</sub>/reference value = 18.0; <sup>3</sup>ligand efficiency (LE): Gibbs free energy (G)/HAC the number of non-hydrogen atoms (or heavy atom count) reference value = -0.5; <sup>4</sup>estimated BEI-G/MW; <sup>5</sup>estimated SEI, -G/polar surface area (PSA).

## DISCUSSION

Previous researches had revealed that 4-anilinoquinazoline derivatives are EGFR inhibitors as their ATP-binding mimic and binding model might play a crucial role in its EGFR and antiproliferative activities (21). The design strategy of these compounds rose from the binding mode action of different substitutions on aniline moiety attached to the C<sub>4</sub> position of the quinazoline ring. The presence of cyclic or linear ether chain and difluoro substitutions on the quinazoline nucleus are also effective. Structure-activity relationship (SAR) studies at cellular level for our 4-anilinoquinazolines demonstrated that compounds with cyclic ether (**9-13**) displayed more potent activities than those with linear ether (**14-18**) and difluoro analogues (**4-8**). It was reported that quinazoline nucleus interact with Met769 and Thr766 in the enzyme active site via two hydrogen bonds. In the binding site of EGFR there is also a lipophilic pocket, which occupied by the aniline ring of 4-anilinoquinazolines. In these type of quinazoline compounds substitutions at C-6 and C-7 of the quinazoline core act to improve the physical properties (22,23). Docking analysis and binding mode of designed compounds on EGFR made evident of polar interactions with two key residues: Met769 and Thr766 in most compounds. On the other hand binding indices calculation could correlate the experimental data with docking results. Similar trend exhibited in antiproliferative activities and LE against EGFR TK target. It demonstrated LE could predict the potency in parallel to the cytotoxic activity on the two tested cell lines.

## CONCLUSION

Here we investigated some erlotinib analogues with 4-anilinoquinazoline scaffold which all have shown good cytotoxic activity. The docking studies simulated all tested compounds to the active site of EGFR TK target. The results revealed the polar interaction between quinazoline backbone and Met769 and Thr766 in catalytic active site.

Additionally, the substitution on aniline moiety particularly ether and cyano played important roles in drug-receptor interactions. Furthermore, calculation of LE indices suggested a good prediction of binding parameters for target compounds and erlotinib as EGFR inhibitors for our future research. We hope the outcomes from the present study may be useful in future drug discovery and investigation of SAR of novel potent 4-anilinoquinazoline with cyclic ether substitution as potent EGFR inhibitors

## ACKNOWLEDGMENT

This work was financially supported by a research Grant No. 89-01-36-2486 provided by the Vice Chancellery of Research of Shiraz University of Medical Sciences, Shiraz, I.R. Iran. The authors also thank Osveh Pharmaceutical Company for supplying the Imatinib powder.

## REFERENCES

1. Polyak K. Heterogeneity in breast cancer. *J Clin Invest.* 2011;121(10):3786-3788.
2. Tseng LM, Chen YT, Huang CT, Chu PY, Wang WL, Liu CY, *et al.* Erlotinib derivative, devoid of EGFR kinase inhibiting effect, induced apoptosis of triple-negative breast cancer cells through modulating Elk-1/CIP2A signaling pathway. *AACR.* 2016;76(14).
3. Haines E, Schlienger S, Claing A. The small GTPase ADP-ribosylation factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. *Cancer Biol Ther.* 2015;16(10):1535-1547.
4. Noolvi MN, Patel HM. Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach: 1st Cancer Update. *Arabian J Chem.* 2013;6(1):35-48.
5. Li RD, Zhang X, Li QY, Ge ZM, Li RT. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. *Bioorg Med Chem Lett.* 2011;21(12):3637-3640.
6. Waiker DK, Karthikeyan C, Poongavanam V, Kongsted J, Lozach O, Meijer L, *et al.* Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors. *Bioorg Med Chem.* 2014;22(6):1909-1915.
7. Mowafy S, Farag NA, Abouzid KA. Design, synthesis and in vitro anti-proliferative activity of

- 4,6-quinazolinediamines as potent EGFR-TK inhibitors. *Eur J Med Chem.* 2013;61:132-145.
8. Lü S, Zheng W, Ji L, Luo Q, Hao X, Li X, *et al.* Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. *Eur J Med Chem.* 2013;61:84-94.
  9. Nasab RR, Hassanzadeh F, Khodarahmi GA, Mirzaei M, Rostami M, Abadi AJ. Synthesis, characterization, cytotoxic screening, and density functional theory studies of new derivatives of quinazolin-4 (3H)-one Schiff bases. *Res Pharm Sci.* 2017;12(6):444-455.
  10. Jafari E, Khajouei MR, Hassanzadeh F, Hakimelahi GH, Khodarahmi GA. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities. *Res Pharm Sci.* 2016;11(1):1-14.
  11. Zhu Y, Wang Y, Guan B, Rao Q, Wang J, Ma H, *et al.* C-kit and PDGFRA gene mutations in triple negative breast cancer. *Int J Clin Exp Pathol.* 2014;7(7):4280-4285.
  12. Wang YL, Overstreet AM, Chen MS, Wang J, Zhao HJ, Ho PC, *et al.* Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR. *Oncotarget.* 2015;6(13):11150-11161.
  13. Haghijoo Z, Rezaei Z, Taheri S, Jani M, Khabnadideh S. A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives. *Trends Pharmacol Sci.* 2015;1(3):173-178.
  14. Haghijoo Z, Eskandari M, Khabnadideh S. Method optimization for synthesis of trisubstituted quinazoline derivatives. *Med Res Arch.* 2017;5(5).
  15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods.* 1983; 65(1-2):55-63.
  16. Mohammadi-Farani A, Foroumadi A, Rezvani Kashani M, Aliabadi A. N-Phenyl-2-p-tolylthiazole-4-carboxamide derivatives: Synthesis and cytotoxicity evaluation as anticancer agents. *Iran J Basic Med Sci.* 2014;17(7):502-508.
  17. Aliabadi A, Hasanvand Z, Kiani A, Mirabdali SS. Synthesis and in-vitro cytotoxicity assessment of N-(5-(Benzylthio)-1, 3, 4-thiadiazol-2-yl)-2-(4-(trifluoromethyl) phenyl) acetamide with potential anticancer activity. *Iran J Pharm Res.* 2013;12(4): 687-693.
  18. Abad-Zapatero C, Metz JT. Ligand efficiency indices as guideposts for drug discovery. *Drug Discov Today.* 2005;10(7):464-469.
  19. Abad-Zapatero C, Perišić O, Wass J, Bento AP, Overington J, Al-Lazikani B, *et al.* Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. *Drug Discov Today.* 2010;15 (19-20):804-811.
  20. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. *Expert Opin Drug Discov.* 2007;2(4):469-488.
  21. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. *J Biol Chem.* 2002;277(48):46265-46272.
  22. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene.* 2009;28(Suppl 1):S24-S31.
  23. Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. *Biochem J.* 2012;448(3):417-423.